Education
About Us
Working with TipRanks
Follow Us
BioAge Labs, Inc. (BIOA)
NASDAQ:BIOA
BIOA Analyst Ratings
Moderate Buy
1 Buy
2 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
BIOA Stock 12 Month Forecast
Average Price Target
$13.50
▲(8.35% Upside)
| Highest Price Target$15.00 | Average Price Target$13.50 | Lowest Price Target$12.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
Morgan Stanley
$5→$12
Hold
-3.69%
Downside
Upgraded
12/08/25
William Blair
―
Hold
―
Reiterated
12/04/25
Analysts' Opinions Are Mixed on These Healthcare Stocks: BioAge Labs, Inc. (NASDAQ: BIOA) and Insulet (NASDAQ: PODD)We view the initial clinical data as a promising start to BGE-102’s development. We believe the company has accomplished four objectives with the SAD and initial MAD results disclosure. First, the PK profile is supportive of once-daily dosing. Second, CSF concentrations of BGE-102 (and potentially its active metabolites) at 60 mg exceeded IC 90 after 14 days of treatment. Third, IL-1β reduction (based on ex vivo whole blood stimulation assay) suggests target engagement and validates the mechanism of action since IL-1β is a cytokine directly downstream of NLRP3. Fourth, the tolerability profile is so far unremarkable. There is a recent investor resurgence in the NLRP3 pathway.
Citi
$15
Buy
20.39%
Upside
Reiterated
12/04/25
Positive Developments and Promising Trials Bolster Buy Rating for BioAge LabsWe utilize a -50% terminal growth rate to account for loss of exclusivity for BioAge’s assets while also providing some value for potential for future assets generated from BioAge’s proprietary platform. We then discount cash flows by 15% annually. Within our coverage, we utilize a 15% discount rate for companies that have not yet established clinical proof-of- concept.
Jefferies
$7
Hold
-43.82%
Downside
Reiterated
03/20/25
Analyst Type
Any
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Morgan Stanley
$5→$12
Hold
-3.69%
Downside
Upgraded
12/08/25
William Blair
―
Hold
―
Reiterated
12/04/25
Analysts' Opinions Are Mixed on These Healthcare Stocks: BioAge Labs, Inc. (NASDAQ: BIOA) and Insulet (NASDAQ: PODD)We view the initial clinical data as a promising start to BGE-102’s development. We believe the company has accomplished four objectives with the SAD and initial MAD results disclosure. First, the PK profile is supportive of once-daily dosing. Second, CSF concentrations of BGE-102 (and potentially its active metabolites) at 60 mg exceeded IC 90 after 14 days of treatment. Third, IL-1β reduction (based on ex vivo whole blood stimulation assay) suggests target engagement and validates the mechanism of action since IL-1β is a cytokine directly downstream of NLRP3. Fourth, the tolerability profile is so far unremarkable. There is a recent investor resurgence in the NLRP3 pathway.
Citi
$15
Buy
20.39%
Upside
Reiterated
12/04/25
Positive Developments and Promising Trials Bolster Buy Rating for BioAge LabsWe utilize a -50% terminal growth rate to account for loss of exclusivity for BioAge’s assets while also providing some value for potential for future assets generated from BioAge’s proprietary platform. We then discount cash flows by 15% annually. Within our coverage, we utilize a 15% discount rate for companies that have not yet established clinical proof-of- concept.
Jefferies
$7
Hold
-43.82%
Downside
Reiterated
03/20/25
Best Analysts Covering BioAge Labs, Inc.
1 Month
xxx
Success Rate
2/3 ratings generated profit
Average Return
+2.67%
reiterated a xxx
rating 13 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 66.67% of your transactions generating a profit, with an average return of +2.67% per trade.
3 Months
xxx
Success Rate
2/3 ratings generated profit
Average Return
-1.70%
reiterated a xxx
rating 13 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 66.67% of your transactions generating a profit, with an average return of -1.70% per trade.
1 Year
Success Rate
2/3 ratings generated profit
Average Return
-1.70%
reiterated a buy rating 13 days ago
Copying Samantha Semenkow's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of -1.70% per trade.
2 Years
xxx
Success Rate
2/3 ratings generated profit
Average Return
-1.70%
reiterated a xxx
rating 13 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 66.67% of your transactions generating a profit, with an average return of -1.70% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
BIOA Analyst Recommendation Trends
Rating
Jun 25
Aug 25
Oct 25
Nov 25
Dec 25
Strong Buy
0
0
1
1
1
Buy
0
0
1
1
2
Hold
5
3
1
2
3
Sell
6
5
4
3
1
Strong Sell
0
0
0
0
0
total
11
8
7
7
7
Each month's total comprises the sum of three months' worth of ratings.
BIOA Financial Forecast
BIOA Stock Forecast FAQ
What is BIOA’s average 12-month price target, according to analysts?
Based on analyst ratings, BioAge Labs, Inc.’s 12-month average price target is 13.50.
What is BIOA’s upside potential, based on the analysts’ average price target?
BioAge Labs, Inc. has 8.35% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is BIOA a Buy, Sell or Hold?
BioAge Labs, Inc. has a consensus rating of Moderate Buy which is based on 1 buy ratings, 2 hold ratings and 0 sell ratings.
What is BioAge Labs, Inc.’s price target?
The average price target for BioAge Labs, Inc. is 13.50. This is based on 3 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $15.00 ,the lowest forecast is $12.00. The average price target represents 8.35% Increase from the current price of $12.46.
The highest analyst price target is $15.00 ,the lowest forecast is $12.00. The average price target represents 8.35% Increase from the current price of $12.46.
What do analysts say about BioAge Labs, Inc.?
BioAge Labs, Inc.’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 3 Wall Streets Analysts.
How can I buy shares of BIOA?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.